Effect of co-administration of Olmesartan and Azelnidipine on vascular endothelial function in patients with atherosclerosis-prone conditions.

Effect of co-administration of Olmesartan and Azelnidipine on vascular endothelial function in patients with atherosclerosis-prone conditions. - Effect of Olmesartan and Azelnidipine on endothelial function.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004479

Enrollment

Registered

2010-10-30

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hypertension and atherosclerosis-prone conditions.

Interventions

After the dual treatment with valsartan (80 mg/day) and amlodipine (5 mg/day) for 6 weeks, the dual treatment is switched to the treatment with olmesartan (20 mg/day) and azelnidipine (16 mg/day) for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) stable hypertension patients treated with valsartan (80 mg/day) and amlodipine (5 mg/day) 2) stable hypertension patients treated with olmesartan (20 mg/day) and azelnidipine (16 mg/day)

Exclusion criteria

Exclusion criteria: poor controlDM (HbA1c > 8%) or inslin usage severe liver and/or renal dysfunction moderate to severe heart failure (< 3 weeks) modelate to severe heart failure (BNP > 200 pg/mL) impossible to fix the dose oftreatments

Design outcomes

Primary

Measure	Time frame
vascular endothelial function index	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026